Business Wire

ADVA, BT and Mavenir Collaborate on Cloud RAN Technologies as Part of Telecom Infra Project

Del

ADVA, BT and Mavenir have announced that they will be collaborating on a number of research projects at the UK’s Telecom Infra Project (TIP) Community Lab based at the BT Labs in Adastral Park, Ipswich.

TIP is an engineering-focused initiative driven by operators, suppliers, developers, integrators, and startups, aimed at challenging the traditional methods used for the deployment of network infrastructure.

At the BT Labs, ADVA, BT and Mavenir will be testing and validating the benefits of Cloud RAN (vRAN) using non-ideal infrastructure for fronthaul, to try and promote innovation in future mobile network deployments. The approach is to investigate and test solutions that will dynamically reduce the cost of future network deployment by reconsidering fronthaul technologies that have previously been rejected.

Today, the fronthaul between the BaseBand Control Unit (BBU) and the Remote Radio Unit (RRU) typically utilizes a fibre optic based transmission medium incorporating a proprietary CPRI (Common Public Radio Interface) specification. This interface has restricted innovation and excluded low-cost deployment technologies such as Ethernet or point-to-point microwave. For many parts of the world where fibre is too costly or difficult to obtain, operators are unable to deploy vRAN technology. The project aims to change the status quo by evaluating fronthaul interfaces that use only one tenth of the current bandwidth and support high latencies, thereby enabling the use of copper Ethernet connections or point-to-point microwaves.

The initiative has reached the testing phase with the deployment of an end-to-end vRAN system incorporating Mavenir and ADVA technologies.

“It’s great to be collaborating with a number of partners at our dedicated TIP Lab in Adastral Park. The results of our research so far into Cloud RAN and fronthaul demonstrate that an Ethernet medium using CAT 5 Connectivity uses one tenth of the bandwidth when compared to a CPRI interface,” said Richard MacKenzie, Principal Researcher, BT.

“This project will also demonstrate the ability to mix RRU suppliers connected to the Mavenir virtual BBU supported on COTs white box platforms. Through this testing and mix of suppliers, we are demonstrating that we can truly disrupt the current ecosystem.”

“We are excited about the challenges presented by TIP and are pleased to support these activities as we continue to deploy Open Interface Cloud RAN in other TIP Community Labs,” said John Baker, SVP Access Business Development at Mavenir. “Cloud RAN can save the carrier greater than 37% in both OPEX and Capex using non-fibre optic solutions.”

“At ADVA, we firmly believe that the virtualization of the RAN is one of the critical building blocks in creating tomorrow’s mobile networks. That’s why we’re so focused on helping to drive TIP’s vRAN Fronthaul project forward,” said James Buchanan, General Manager at ADVA’s Ensemble Division. “Within this project, we’re using our Ensemble Connector to show how simple it is to host vRANs on white boxes. In fact, we’re showcasing the solution this month on our booth at Mobile World Congress, Barcelona. What we’re demonstrating in Barcelona is the first step on the path to vRAN commercialization. What follows next is to clearly define the underlying requirements of the transport and Carrier Ethernet network, including synchronization and OAM – something we’re working on closely with BT, Mavenir and our other TIP vRAN Fronthaul Project Group partners.”

About ADVA Optical Networking:

ADVA Optical Networking is a company founded on innovation and driven to help our customers succeed. For over two decades, our technology has empowered networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information, please visit www.advaoptical.com.

About BT:

BT’s purpose is to use the power of communications to make a better world. It is one of the world’s leading providers of communications services and solutions, serving customers in 180 countries. Its principal activities include the provision of networked IT services globally; local, national and international telecommunications services to its customers for use at home, at work and on the move; broadband, TV and internet products and services; and converged fixed-mobile products and services. BT consists of six customer-facing lines of business: Consumer, EE, Business and Public Sector, Global Services, Wholesale and Ventures, and Openreach.

For the year ended 31 March 2017, BT Group’s reported revenue was £24,062m with reported profit before taxation of £2,354m.

British Telecommunications plc (BT) is a wholly-owned subsidiary of BT Group plc and encompasses virtually all businesses and assets of the BT Group. BT Group plc is listed on stock exchanges in London and New York. For more information, visit www.btplc.com

About TIP:

Founded February 2016, the Telecom Infra Project (TIP) is an engineering-focused initiative driven by operators, suppliers, developers, integrators, and startups to disaggregate the traditional network deployment approach. The collective aim of our community is to collaborate on new technologies, examine new business approaches and spur new investments into the telecom space.

About Mavenir:

Mavenir is purpose-built to redefine mobile network economics for Communication Service Providers (CSPs). Our solutions pave the way to 5G with 100% software-based, end-to-end, Cloud Native network solutions. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC and Cloud RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, serving over 50% of the world’s subscribers.

We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to CSPs for revenue generation, cost reduction and revenue protection. Mavenir.com

Contact information

for Mavenir
Media Contacts:
Maryvonne Tubb
pr@mavenir.com
or
Loren Guertin
mavenir@matternow.com
or
Hannah Locke
mavenir@hotwirePR.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A18.6.2018 07:06Pressemelding

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®. New single dose vial strengths of 2500, 3000 and 4000 International Units (IU) will be available in Europe, in addition to the current strengths of 250, 500, 1000 and 2000 IU. The new Nuwiq® vial strengths have been available in the US since September last year, following approval by the FDA. Nuwiq® is indicated in adults and children of all ages for on-demand treatment and prophylaxis, including during surgery, to prevent and control bleeding episodes in patients with haemophilia A. This expanded array of vial strengths has the potential to increase treatment options for patients with haemophilia A by improving dosing flexibility. Patients who previously required more than one vial per infusion may be able to reduce the number of vials needed. Nuwiq® is the only rFVIII available in an

STATS and SpokeHub Partner to Power Deeper, More Meaningful Conversations Around the 2018 FIFA World Cup18.6.2018 07:00Pressemelding

Today, STATS, the worldwide leader in sports data and intelligence, and SpokeHub announced a new partnership to bring STATS Insights to SpokeHub’s social engagement platform, connecting worldwide World Cup football (soccer) fans with content that is more impactful. Download the app today to see the match scores, player insights, and engage with World Cup fans everywhere! STATS Insights leverages more than 37 years of research experience to deliver deep historical and comparative statistical insights, play-by-play descriptions and in-game trends based on events as they happen in the match. Before, during and after each match, SpokeHub will harness STATS Insights to amplify conversations among World Cup football communities. During the game, live Insights will deliver trends on players and teams based on in-game events, statistics and milestones. “No sporting event gets global attention like the World Cup, and every fan is looking for deeper analysis around their favorite teams and playe

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch